EUVIMEDEUVIMED entdecken
Crossref

Artificial intelligence and circulating tumor DNA minimal residual disease in perioperative resectable non-small cell lung cancer

Yang Chen, Wenqi Li, Pengxuan Qiu, Ran Zhong, Boao Jiang, Miao He, Peiling Chen, Huiting Liu, Rui Gao, Xinting Li, Hongsheng Deng, Yu Jiang und 4 weitere

Artificial Intelligence Surgery · 15.07.2026 · 6 (3) · 340-59

DOI: 10.20517/ais.2026.27 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Intelligence Surgery, online erschienen am 15.07.2026. Verfasst von Yang Chen und 15 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite curative-intent treatment, recurrence risk in resectable non-small cell lung cancer (NSCLC) remains difficult to define, and postoperative management still depends on imperfect clinicopathologic assessment. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) has emerged as a promising adjunct for postoperative risk stratification, early relapse detection, and perioperative response assessment. Its clinical translation, however, is still limited by low sensitivity in low-shedding diseases, imperfect specificity from biological background signals, interpretive uncertainty, and a lack of assay standardization. In this context, artificial intelligence (AI) is relevant not as a generic add-on, but as a potential means to improve weak-signal detection, refine variant-origin assignment, and translate serial ctDNA measurements into clinically interpretable risk estimates. This review considers the current clinical role of ctDNA-MRD in perioperative NSCLC, the barriers to routine implementation, and the extent to which AI may help make molecular monitoring more reliable and clinically useful.

Zitieren

APA

Chen, Y., Li, W., Qiu, P., Zhong, R., Jiang, B., He, M., Chen, P., Liu, H., Gao, R., Li, X., Deng, H., Jiang, Y., Lin, Y., Liang, W., He, J., & Liang, H. (2026). Artificial intelligence and circulating tumor DNA minimal residual disease in perioperative resectable non-small cell lung cancer. Artificial Intelligence Surgery, 6(3), 340-59. https://doi.org/10.20517/ais.2026.27

Vancouver

Chen Y, Li W, Qiu P, Zhong R, Jiang B, He M, et al. Artificial intelligence and circulating tumor DNA minimal residual disease in perioperative resectable non-small cell lung cancer. Artificial Intelligence Surgery. 2026;6(3):340-59. doi:10.20517/ais.2026.27

BibTeX
@article{Chen2026,
  author = {Chen, Yang and Li, Wenqi and Qiu, Pengxuan and Zhong, Ran and Jiang, Boao and He, Miao and Chen, Peiling and Liu, Huiting and Gao, Rui and Li, Xinting and Deng, Hongsheng and Jiang, Yu and Lin, Yuechun and Liang, Wenhua and He, Jianxing and Liang, Hengrui},
  title = {Artificial intelligence and circulating tumor DNA minimal residual disease in perioperative resectable non-small cell lung cancer},
  journal = {Artificial Intelligence Surgery},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {340--59},
  doi = {10.20517/ais.2026.27}
}
Kostenlos starten →